Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Graphene biointerfaces for optical stimulation of cells.

Savchenko A, Cherkas V, Liu C, Braun GB, Kleschevnikov A, Miller YI, Molokanova E.

Sci Adv. 2018 May 18;4(5):eaat0351. doi: 10.1126/sciadv.aat0351. eCollection 2018 May.

2.

Developmental excitatory-to-inhibitory GABA polarity switch is delayed in Ts65Dn mice, a genetic model of Down syndrome.

Lysenko LV, Kim J, Madamba F, Tyrtyshnaia AA, Ruparelia A, Kleschevnikov AM.

Neurobiol Dis. 2018 Jul;115:1-8. doi: 10.1016/j.nbd.2018.03.005. Epub 2018 Mar 14.

PMID:
29550538
3.

Neuron-Targeted Caveolin-1 Promotes Ultrastructural and Functional Hippocampal Synaptic Plasticity.

Egawa J, Zemljic-Harpf A, Mandyam CD, Niesman IR, Lysenko LV, Kleschevnikov AM, Roth DM, Patel HH, Patel PM, Head BP.

Cereb Cortex. 2018 Sep 1;28(9):3255-3266. doi: 10.1093/cercor/bhx196.

PMID:
28981594
4.

Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

Kleschevnikov AM, Yu J, Kim J, Lysenko LV, Zeng Z, Yu YE, Mobley WC.

Neurobiol Dis. 2017 Jul;103:1-10. doi: 10.1016/j.nbd.2017.03.009. Epub 2017 Mar 22.

5.

Acute neuroinflammation provokes intracellular acidification in mouse hippocampus.

Tyrtyshnaia AA, Lysenko LV, Madamba F, Manzhulo IV, Khotimchenko MY, Kleschevnikov AM.

J Neuroinflammation. 2016 Nov 3;13(1):283.

6.

GABAergic hyperinnervation of dentate granule cells in the Ts65Dn mouse model of down syndrome: Exploring the role of App.

Mojabi FS, Fahimi A, Moghadam S, Moghadam S, Windy McNerneny M, Ponnusamy R, Kleschevnikov A, Mobley WC, Salehi A.

Hippocampus. 2016 Dec;26(12):1641-1654. doi: 10.1002/hipo.22664. Epub 2016 Oct 24.

PMID:
27701794
7.

An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.

Belichenko PV, Madani R, Rey-Bellet L, Pihlgren M, Becker A, Plassard A, Vuillermot S, Giriens V, Nosheny RL, Kleschevnikov AM, Valletta JS, Bengtsson SK, Linke GR, Maloney MT, Hickman DT, Reis P, Granet A, Mlaki D, Lopez-Deber MP, Do L, Singhal N, Masliah E, Pearn ML, Pfeifer A, Muhs A, Mobley WC.

PLoS One. 2016 Mar 29;11(3):e0152471. doi: 10.1371/journal.pone.0152471. eCollection 2016.

8.

Genetic dissection of the Down syndrome critical region.

Jiang X, Liu C, Yu T, Zhang L, Meng K, Xing Z, Belichenko PV, Kleschevnikov AM, Pao A, Peresie J, Wie S, Mobley WC, Yu YE.

Hum Mol Genet. 2015 Nov 15;24(22):6540-51. doi: 10.1093/hmg/ddv364. Epub 2015 Sep 15.

9.

Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues.

Belichenko PV, Kleschevnikov AM, Becker A, Wagner GE, Lysenko LV, Yu YE, Mobley WC.

PLoS One. 2015 Jul 31;10(7):e0134861. doi: 10.1371/journal.pone.0134861. eCollection 2015.

10.

Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome.

Lysenko LV, Kim J, Henry C, Tyrtyshnaia A, Kohnz RA, Madamba F, Simon GM, Kleschevnikova NE, Nomura DK, Ezekowitz RA, Kleschevnikov AM.

PLoS One. 2014 Dec 4;9(12):e114521. doi: 10.1371/journal.pone.0114521. eCollection 2014.

11.

Traumatic brain injury enhances neuroinflammation and lesion volume in caveolin deficient mice.

Niesman IR, Schilling JM, Shapiro LA, Kellerhals SE, Bonds JA, Kleschevnikov AM, Cui W, Voong A, Krajewski S, Ali SS, Roth DM, Patel HH, Patel PM, Head BP.

J Neuroinflammation. 2014 Mar 3;11:39. doi: 10.1186/1742-2094-11-39.

12.

Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits.

Zhang L, Meng K, Jiang X, Liu C, Pao A, Belichenko PV, Kleschevnikov AM, Josselyn S, Liang P, Ye P, Mobley WC, Yu YE.

Hum Mol Genet. 2014 Feb 1;23(3):578-89. doi: 10.1093/hmg/ddt446. Epub 2013 Sep 16.

13.

Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.

Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC.

J Neurosci. 2012 Jul 4;32(27):9217-27. doi: 10.1523/JNEUROSCI.1673-12.2012.

14.

Discoveries in Down syndrome: moving basic science to clinical care.

Kleschevnikov AM, Belichenko PV, Salehi A, Wu C.

Prog Brain Res. 2012;197:199-221. doi: 10.1016/B978-0-444-54299-1.00010-8. Review.

PMID:
22541294
15.

Genetic analysis of Down syndrome facilitated by mouse chromosome engineering.

Zhang L, Fu D, Belichenko PV, Liu C, Kleschevnikov AM, Pao A, Liang P, Clapcote SJ, Mobley WC, Yu YE.

Bioeng Bugs. 2012 Jan 1;3(1):8-12. doi: 10.4161/bbug.3.1.17696. Epub 2012 Jan 1.

16.

Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.

Kleschevnikov AM, Belichenko PV, Gall J, George L, Nosheny R, Maloney MT, Salehi A, Mobley WC.

Neurobiol Dis. 2012 Feb;45(2):683-91. doi: 10.1016/j.nbd.2011.10.009. Epub 2011 Oct 17.

17.

Mouse models for Down syndrome-associated developmental cognitive disabilities.

Liu C, Belichenko PV, Zhang L, Fu D, Kleschevnikov AM, Baldini A, Antonarakis SE, Mobley WC, Yu YE.

Dev Neurosci. 2011;33(5):404-13. doi: 10.1159/000329422. Epub 2011 Aug 25. Review.

18.

Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.

Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, Saw N, Priestley M, Tsien RW, Mobley WC, Shamloo M.

Neurobiol Dis. 2011 Aug;43(2):397-413. doi: 10.1016/j.nbd.2011.04.011. Epub 2011 Apr 17.

19.

Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome.

Popov VI, Kleschevnikov AM, Klimenko OA, Stewart MG, Belichenko PV.

J Comp Neurol. 2011 May 1;519(7):1338-54. doi: 10.1002/cne.22573.

PMID:
21452200
20.

Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice.

Yu T, Liu C, Belichenko P, Clapcote SJ, Li S, Pao A, Kleschevnikov A, Bechard AR, Asrar S, Chen R, Fan N, Zhou Z, Jia Z, Chen C, Roder JC, Liu B, Baldini A, Mobley WC, Yu YE.

Brain Res. 2010 Dec 17;1366:162-71. doi: 10.1016/j.brainres.2010.09.107. Epub 2010 Oct 26.

21.

Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome.

Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M, Mobley WC.

Sci Transl Med. 2009 Nov 18;1(7):7ra17. doi: 10.1126/scitranslmed.3000258.

22.

The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome.

Belichenko NP, Belichenko PV, Kleschevnikov AM, Salehi A, Reeves RH, Mobley WC.

J Neurosci. 2009 May 6;29(18):5938-48. doi: 10.1523/JNEUROSCI.1547-09.2009.

23.

Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome.

Belichenko PV, Kleschevnikov AM, Masliah E, Wu C, Takimoto-Kimura R, Salehi A, Mobley WC.

J Comp Neurol. 2009 Feb 1;512(4):453-66. doi: 10.1002/cne.21895.

PMID:
19034952
24.

Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships.

Belichenko PV, Kleschevnikov AM, Salehi A, Epstein CJ, Mobley WC.

J Comp Neurol. 2007 Oct 1;504(4):329-45.

PMID:
17663443
25.

Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.

Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kulnane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC.

Neuron. 2006 Jul 6;51(1):29-42.

26.

Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome.

Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, Mobley WC.

J Comp Neurol. 2004 Dec 13;480(3):281-98.

PMID:
15515178
27.

Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.

Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC.

J Neurosci. 2004 Sep 15;24(37):8153-60.

28.

Long-term potentiation recruits a trisynaptic excitatory associative network within the mouse dentate gyrus.

Kleschevnikov AM, Routtenberg A.

Eur J Neurosci. 2003 Jun;17(12):2690-702. Erratum in: Eur J Neurosci. 2003 Sep;18(6):1717.

PMID:
12823476
29.

PKC activation rescues LTP from NMDA receptor blockade.

Kleschevnikov AM, Routtenberg A.

Hippocampus. 2001;11(2):168-75.

PMID:
11345123
31.

Changes in paired-pulse facilitation correlate with induction of long-term potentiation in area CA1 of rat hippocampal slices.

Kleschevnikov AM, Sokolov MV, Kuhnt U, Dawe GS, Stephenson JD, Voronin LL.

Neuroscience. 1997 Feb;76(3):829-43.

PMID:
9135055
32.

Atropine suppresses associative LTP in the CA1 region of rat hippocampal slices.

Sokolov MV, Kleschevnikov AM.

Brain Res. 1995 Feb 20;672(1-2):281-4.

PMID:
7749748
33.

Neurophysiological analysis of long-term potentiation in mammalian brain.

Voronin L, Byzov A, Kleschevnikov A, Kozhemyakin M, Kuhnt U, Volgushev M.

Behav Brain Res. 1995 Jan 23;66(1-2):45-52. Review.

PMID:
7755898
35.

The M1 antagonist pirenzepine suppresses heterosynaptic STD in the CA1 region.

Kozhemyakin MB, Kleschevnikov AM.

Neuroreport. 1994 Aug 15;5(13):1670-2.

PMID:
7819544

Supplemental Content

Loading ...
Support Center